Differences in the erythropoiesis-hepcidin-iron store axis between hemoglobin H disease and β-thalassemia intermedia.
作者信息
Origa Raffaella, Cazzola Mario, Mereu Elisabetta, Danjou Fabrice, Barella Susanna, Giagu Nicolina, Galanello Renzo, Swinkels Dorine W
机构信息
Ospedale Microcitemico-Department of Public Health, Clinical and Molecular Medicine, University of Cagliari, Italy.
Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, and Department of Molecular Medicine, University of Pavia, Italy.
出版信息
Haematologica. 2015 May;100(5):e169-71. doi: 10.3324/haematol.2014.115733. Epub 2015 Jan 16.
Abstract
摘要
相似文献
1
Differences in the erythropoiesis-hepcidin-iron store axis between hemoglobin H disease and β-thalassemia intermedia.
Haematologica. 2015 May;100(5):e169-71. doi: 10.3324/haematol.2014.115733. Epub 2015 Jan 16.
2
Hepcidin is suppressed by erythropoiesis in hemoglobin E β-thalassemia and β-thalassemia trait.
Blood. 2015 Jan 29;125(5):873-80. doi: 10.1182/blood-2014-10-606491. Epub 2014 Dec 17.
3
mRNA expression of iron regulatory genes in beta-thalassemia intermedia and beta-thalassemia major mouse models.
Am J Hematol. 2006 Jul;81(7):479-83. doi: 10.1002/ajh.20549.
4
Hepcidin independent iron recycling in a mouse model of β-thalassaemia intermedia.
Br J Haematol. 2016 Oct;175(2):308-317. doi: 10.1111/bjh.14206. Epub 2016 Jul 13.
5
Analysis of Glycosylation Profiles of Serum Glycoprotein from Iron Overload Thalassemia.
Clin Lab. 2018 Jul 1;64(7):1279-1287. doi: 10.7754/Clin.Lab.2018.180319.
6
Iron Status in Newly Diagnosed -Thalassemia Major: High Rate of Iron Status due to Erythropoiesis Drive.
Biomed Res Int. 2021 Apr 16;2021:5560319. doi: 10.1155/2021/5560319. eCollection 2021.
7
Serum Hepcidin as a Diagnostic Marker of Severe Iron Overload in Beta-thalassemia Major.
Indian J Pediatr. 2017 Oct;84(10):745-750. doi: 10.1007/s12098-017-2375-4. Epub 2017 Jun 10.
8
Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches.
Hematol Oncol Clin North Am. 2014 Apr;28(2):387-401. doi: 10.1016/j.hoc.2013.11.004. Epub 2014 Jan 18.
9
Imbalance of erythropoiesis and iron metabolism in patients with thalassemia.
Int J Med Sci. 2019 Jan 1;16(2):302-310. doi: 10.7150/ijms.27829. eCollection 2019.
10
Stimulated erythropoiesis with secondary iron loading leads to a decrease in hepcidin despite an increase in bone morphogenetic protein 6 expression.
Br J Haematol. 2012 Jun;157(5):615-26. doi: 10.1111/j.1365-2141.2012.09104.x. Epub 2012 Mar 26.
引用本文的文献
1
Incidence of cancer and related deaths in hemoglobinopathies: A follow-up of 4631 patients between 1970 and 2021.
Cancer. 2023 Jan 1;129(1):107-117. doi: 10.1002/cncr.34509. Epub 2022 Nov 2.
2
Thalassemia Intermedia: Chelator or Not?
Int J Mol Sci. 2022 Sep 5;23(17):10189. doi: 10.3390/ijms231710189.
3
Phosphatidylserine-exposed red blood cells and ineffective erythropoiesis biomarkers in patients with thalassemia.
Am J Transl Res. 2022 Jul 15;14(7):4743-4756. eCollection 2022.
4
Iron overload disorders.
Hepatol Commun. 2022 Aug;6(8):1842-1854. doi: 10.1002/hep4.2012. Epub 2022 Jun 14.
5
Clinical interpretation of serum hepcidin-25 in inflammation and renal dysfunction.
J Mass Spectrom Adv Clin Lab. 2022 Mar 28;24:43-49. doi: 10.1016/j.jmsacl.2022.03.002. eCollection 2022 Apr.
6
Novel Therapeutic Advances in β-Thalassemia.
Biology (Basel). 2021 Jun 18;10(6):546. doi: 10.3390/biology10060546.
7
The Interplay between Drivers of Erythropoiesis and Iron Homeostasis in Rare Hereditary Anemias: Tipping the Balance.
Int J Mol Sci. 2021 Feb 23;22(4):2204. doi: 10.3390/ijms22042204.
8
Erythropoiesis and Iron Homeostasis in Non-Transfusion-Dependent Thalassemia Patients with Extramedullary Hematopoiesis.
Biomed Res Int. 2019 Jan 30;2019:4504302. doi: 10.1155/2019/4504302. eCollection 2019.
9
Imbalance of erythropoiesis and iron metabolism in patients with thalassemia.
Int J Med Sci. 2019 Jan 1;16(2):302-310. doi: 10.7150/ijms.27829. eCollection 2019.
10
EPO and hepcidin plasma concentrations in blood donors and β-thalassemia intermedia are not related to commercially tested plasma ERFE concentrations.
Am J Hematol. 2017 Mar;92(3):E29-E31. doi: 10.1002/ajh.24636.
本文引用的文献
1
Identification of erythroferrone as an erythroid regulator of iron metabolism.
Nat Genet. 2014 Jul;46(7):678-84. doi: 10.1038/ng.2996. Epub 2014 Jun 1.
2
Hepcidin in human iron disorders: diagnostic implications.
Clin Chem. 2011 Dec;57(12):1650-69. doi: 10.1373/clinchem.2009.140053. Epub 2011 Oct 11.
3
Serum hepcidin: reference ranges and biochemical correlates in the general population.
Blood. 2011 Jun 23;117(25):e218-25. doi: 10.1182/blood-2011-02-337907. Epub 2011 Apr 28.
4
Immunochemical and mass-spectrometry-based serum hepcidin assays for iron metabolism disorders.
Clin Chem. 2010 Oct;56(10):1570-9. doi: 10.1373/clinchem.2010.149187. Epub 2010 Aug 25.
5
Hb H disease: clinical course and disease modifiers.
Hematology Am Soc Hematol Educ Program. 2009:26-34. doi: 10.1182/asheducation-2009.1.26.
6
Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells.
Blood. 2009 Jul 2;114(1):181-6. doi: 10.1182/blood-2008-12-195503. Epub 2009 May 4.
7
High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin.
Nat Med. 2007 Sep;13(9):1096-101. doi: 10.1038/nm1629. Epub 2007 Aug 26.
8
Liver iron concentrations and urinary hepcidin in beta-thalassemia.
Haematologica. 2007 May;92(5):583-8. doi: 10.3324/haematol.10842.
9
Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin.
Blood. 2007 Jun 1;109(11):5027-35. doi: 10.1182/blood-2006-09-048868. Epub 2007 Feb 13.
10
Hepcidin in iron overload disorders.
Blood. 2005 May 15;105(10):4103-5. doi: 10.1182/blood-2004-12-4844. Epub 2005 Jan 25.
Zotero 插件